Primary prevention of cardiovascular disease: Time to get more or less personal?

JAMA

Volumn 302, Issue 19, 2009, Pages 2144-2145

  Hingorani, Aroon D ^a   Psaty, Bruce M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; LIFESTYLE MODIFICATION; NOTE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; SODIUM RESTRICTION; STROKE; UNITED KINGDOM; UNITED STATES;

CARDIOVASCULAR DISEASES; COMPARATIVE EFFECTIVENESS RESEARCH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDIVIDUALIZED MEDICINE; PRIMARY PREVENTION; RISK ASSESSMENT;

EID: 71749094382     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1698     Document Type: Note

References (10)

1. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14(1):32-38.
2. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366(9494):1358]. Lancet. 2005;355:1267-1278.
3. Wald NJ, Morris JK, Rish S. The efficacy of combining several risk factors as a screening test. J Med Screen. 2005;12(4):197-201. (Pubitemid 43843295)
4. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897-1908.
5. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38(1):217-231.
6. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med. 2009;150(11):795-802.
7. National Institute for Health and Clinical Excellence. Putting prevention first - vascular checks: risk assessment and management. http://www.dh.gov.uk/ en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH-083822. Accessed August 17, 2009.
8. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.
9. Yusuf S, Pais P, Afzal R, et al; Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double blind, randomised trial. Lancet. 2009;373:1341-1351.
10. Institute of Medicine Committee on Comparative Effectiveness Research Prioritization. Initial national priorities for comparative effectiveness research: report brief. Institute of Medicine of the National Academies 2009. http://www.iom.edu/en/Reports/2009/ComparativeEffectivenessResearchPriorities. aspx. Accessed August 26, 2009.